Phospho-p70 S6 Kinase Beta (Thr228)抗体特异性结合抗原：抗体本身不能直接溶解或杀伤带有特异抗原的靶细胞，通常需要补体或吞噬细胞等共同发挥效应以**病原微生物或导致病理损伤。然而，抗体可通过与病毒或**的特异性结合，直接发挥中和病毒的作用。
产品编号xy- 3499R
英文名称Phospho-p70 S6 Kinase Beta (Thr228)
中文名称磷酸化核糖体S6蛋白激酶β2抗体
别 名P70 S6 Kinase beta (phospho Thr228); P70 S6 Kinase beta (phospho-T228); p-P70 S6 Kinase beta (Thr228); p-P70 S6 Kinase beta (T228); 70 kDa ribosomal protein S6 kinase 2; EC 2.7.11.1; KS6B2_HUMAN; p70 beta; p70 ribosomal S6 kinase beta; p70 S6 kinase beta; p70 S6K-beta; p70 S6KB; p70 S6Kbeta; p70(S6K) beta; p70-beta; p70-S6K 2; P70S6K2; p70S6Kb; Ribosomal protein S6 kinase 70kDa, polypeptide 2; Ribosomal protein S6 kinase beta 2; Ribosomal protein S6 kinase beta-2; Rps6kb2; S6 kinase related kinase; S6 kinase-related kinase; S6K beta 2; S6K beta; S6K-beta; S6K-beta-2; S6K2; Serine/threonine protein kinase 14 beta; Serine/threonine-protein kinase 14B; SRK; STK14B.
说 明 书100ul
产品类型磷酸化抗体
研究领域肿瘤 **学 信号转导 细胞凋亡 转录调节因子 激酶和磷酸酶
抗体来源Rabbit
克隆类型Polyclonal
Phospho-p70 S6 Kinase Beta (Thr228)抗体交叉反应 Human, Mouse, Rat, Chicken, Dog, Pig, Cow, Horse,
产品应用WB=1:500-2000 ELISA=1:500-1000 （石蜡切片需做抗原修复）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量59kDa
细胞定位细胞核
性 状Lyophilized or Liquid
浓 度1mg/1ml
免 疫 原KLH conjugated synthesised phosphopeptide derived from human p70 S6 Kinase Beta around the phosphorylation site of Thr228:TH(p-T)FC
亚 型IgG
纯化方法affinity purified by Protein A
储 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Phospho-p70 S6 Kinase Beta (Thr228)抗体保存条件Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
PubMedPubMed
产品介绍background:
This gene encodes a member of the ribosomal S6 kinase family of serine/threonine kinases. The encoded protein responds to mTOR (mammalian target of rapamycin) signaling to promote protein synthesis, cell growth, and cell proliferation. Activity of this gene has been associated with human cancer. Alternatively spliced transcript variants have been observed. The use of alternative translation start sites results in isoforms with longer or shorter N-termini which may differ in their subcellular localizations. There are two pseudogenes for this gene on chromosome 17. [provided by RefSeq, Jan 2013].
Function:
Serine/threonine-protein kinase that acts downstream of mTOR signaling in response to growth factors and nutrients to promote cell proliferation, cell growth and cell cycle progression. Regulates protein synthesis through phosphorylation of EIF4B, RPS6 and EEF2K, and contributes to cell survival by repressing the pro-apoptotic function of BAD. Under conditions of nutrient depletion, the inactive form associates with the EIF3 translation initiation complex. Upon mitogenic stimulation, phosphorylation by the mammalian target of rapamycin complex 1 (mTORC1) leads to dissociation from the EIF3 complex and activation. The active form then phosphorylates and activates several substrates in the preinitiation complex, including the EIF2B complex and the cap-binding complex component EIF4B. Also controls translation initiation by phosphorylating a negative regulator of EIF4A, PDCD4, targeting it for ubiquitination and subsequent proteolysis. Promotes initiation of the pioneer round of protein synthesis by phosphorylating POLDIP3/SKAR. In response to IGF1, activates translation elongation by phosphorylating EEF2 kinase (EEF2K), which leads to its inhibition and thus activation of EEF2. Also plays a role in feedback regulation of mTORC2 by mTORC1 by phosphorylating RICTOR, resulting in the inhibition of mTORC2 and AKT1 signaling. Mediates cell survival by phosphorylating the pro-apoptotic protein BAD and suppressing its pro-apoptotic function. Phosphorylates mitochondrial URI1 leading to dissociation of a URI1-PPP1CC complex. The free mitochondrial PPP1CC can then dephosphorylate RPS6KB1 at 'Thr-412', which is proposed to be a negative feedback mechanism for the RPS6KB1 anti-apoptotic function. Mediates TNF-alpha-induced insulin resistance by phosphorylating IRS1 at multiple serine residues, resulting in accelerated degradation of IRS1. In cells lacking functional TSC1-2 complex, constitutively phosphorylates and inhibits GSK3B. May be involved in cytoskeletal rearrangement through binding to neurabin.
Subunit:
Interacts with PPP1R9A/neurabin-1. Interacts with RPTOR. Interacts with IRS1. Interacts with EIF3B and EIF3C. Interacts with POLDIP3 and TRAF4.
Subcellular Location:
Cell junction, synapse, synaptosome. Mitochondrion outer membrane. Mitochondrion.Note=Colocalizes with URI1 at mitochondrion. Isoform Alpha I: Nucleus. Cytoplasm. Isoform Alpha II: Cytoplasm.
Tissue Specificity:
Widely expressed.
Post-translational modifications:
Phosphorylation at Thr-412 is regulated by mTORC1. The phosphorylation at this site is maintained by an agonist-dependent autophosphorylation mechanism (By similarity). Activated by phosphorylation at Thr-252 by PDPK1. Dephosphorylation by PPP1CC at Thr-412 in mitochondrion.
Similarity:
Belongs to the protein kinase superfamily. AGC Ser/Thr protein kinase family. S6 kinase subfamily.
Contains 1 AGC-kinase C-terminal domain.
Contains 1 protein kinase domain.
SWISS:
Q9UBS0
Gene ID:
6199
Phospho-p70 S6 Kinase Beta (Thr228)抗体（antibody,
Ab）是由效应B细胞（效应**B细胞）分泌，机体用于抵御外来物质，如病毒，**等抗原，结构呈“Y”字型的球状蛋白质，仅仅存在于脊椎动物的血液和B**细胞膜表面。凡是能够跟抗体结合的物质，均被称作抗原，因此对于抗抗体（能够结合抗体的抗体）来说，抗体本身也是一种抗原物质。
Phospho-p70 S6 Kinase Beta (Thr228)抗体普通抗体重链和轻链的结构
重链结构：普通的**球蛋白具有2条重链（H链），分子量约为50kD,有μ、δ、γ、ε和α五种重链亚型，对应的**球蛋白名称分别为IgM、IgG、IgA、IgD和IgE。
轻链结构： 普通**球蛋白具有2条轻链（L链），分子质量约25kDa，有κ链和λ链两种亚型，这两种轻链决定了Ig的亚型类别（IgG1，IgG2，IgG3，IgG4）。一个天然的Ig分子两条轻链总是相同的，但在同一个体内可存在分别带有κ或λ链的抗体分子。不同种属生物体内两型轻链的比例不同，正常人血清**球蛋白κ链：λ链约为2：1，而在小鼠的比例为20：1。
2.2抗体Fab段和Fc段
IgG经木瓜蛋白酶酶切后裂解为2个完全相同的Fab段和1个Fc段,每个Fab段都为单价,可与抗原结合但不会再发生凝集反应；经胃蛋白酶酶切后裂解为1个完整F(ab)2片段和碎片化的Fc片段,F(ab’)2片段为双价,可同时结合两个抗原表位。Fab段为抗原结合片段（fragment of antigen binding，Fab），相当于抗体分子的两个臂，由一个完整的轻链和重链的VH和CH1结构域组成。Fc段为可结晶段（fragment crystallizable，Fc）相当于Ig的CH2和CH3结构域，是Ig与效应分子或者细胞相互作用的部位。Fab段包含完整的可变区，以及恒定区的CH1区域。Fc段仅指Ig恒定区CH2和CH3的区域，相当于Y字结构下面那一部分。
合格 合格 phospho-P53 (Ser15) 磷酸化肿瘤抑制基因P53抗体
合格 合格 phospho-P53 (Ser20) 磷酸化肿瘤抑制基因P53抗体
合格 合格 phospho-P53 (Ser315) 磷酸化肿瘤抑制基因P53抗体
合格 合格 phospho-P53 (Ser33) 磷酸化肿瘤抑制基因P53抗体
合格 合格 phospho-P53(Ser37) 磷酸化肿瘤抑制基因P53抗体
合格 合格 phospho-P53(Ser46) 磷酸化肿瘤抑制基因P53抗体
合格 合格 phospho-P53(Ser6) 磷酸化肿瘤抑制基因P53抗体
合格 phospho-P53(Thr18) 磷酸化肿瘤抑制基因P53抗体
合格 合格 phospho-P53(Thr81) 磷酸化肿瘤抑制基因P53抗体
合格 Phospho-delta Opioid Receptor (Ser363) 磷酸化D型受体抗体
合格 Phospho-p63 (Ser160+Ser162) 磷酸化P63肿瘤抑制基因抗体
合格 phospho-eIF4EBP1 (Ser65 + Thr70) 磷酸化eIF4E结合蛋白抗体
合格 Phospho-CHK2 (Thr68) 磷酸化细胞周期检测点激酶2抗体
合格 合格 phospho-PKC delta (Tyr52) 磷酸化蛋白激酶C亚性D型抗体
合格 合格 phospho-PKC delta (Thr505) 磷酸化蛋白激酶C亚性D型抗体
合格 合格 phospho-PKC delta (Tyr311) 磷酸化蛋白激酶C亚性D型抗体
合格 合格 Phospho-eNOS (Thr495) 磷酸化一氧化氮合成酶3（内皮型）抗体
合格 Phospho-TrkB (Tyr817) 磷酸化酪氨酸激酶B(Tyr817)抗体
合格 合格 Phospho-PPAR Gamma (ser112) 磷酸化过氧化酶活化增生受体γ抗体
合格 phospho-Crkl (Tyr251) 磷酸化接头蛋白CrkL抗体
合格 PNPLA1 含patatin样磷脂酶1抗体
合格 Histone H4 (Acetyl K12) 乙酰化组蛋白H4抗体
合格 BMAL1 芳香烃受体核转录蛋白样1抗体